Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based therapeutics developer Galectin Therapeutics (GALT) has announced that it has teamed up with Dr. Geert-Jan Boons’ laboratory at Georgia University for the establishment of a collaborative drug discovery program for new Anti-Galectin drugs.
Subscribe to our email newsletter
The program will focus on the discovery of new carbohydrate molecules, which can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders.
Galectin Therapeutics president, chief executive officer and chief medical officer Peter Traber said Galectins play an important role in many diseases and developing a pipeline of drugs that can target galectins is an important goal for the firm.
"We are extremely excited about our collaboration with the world-class Complex Carbohydrate Research Center and Dr. Boons, who is a world renowned and preeminent carbohydrate chemist. There is no better place in the world to conduct these investigations than the University of Georgia," Traber said.
Dr. Geert-Jan Boons’ laboratory is located in the Complex Carbohydrate Research Center at the University of Georgia, US.
The Complex Carbohydrate Research Center is the one of the only three centers globally dedicated to the study of complex carbohydrates, which play critical roles in cellular communication, gene expression, immunology, organism defense mechanisms, growth and development.